Lilly starting next phase of Alzheimer’s trial
Eli Lilly and Co. plans to launch a second Phase 3 clinical trial of one of its experimental Alzheimer’s medicines. The Indianapolis-based drugmaker announced today that it hopes to test its gamma secretase inhibitor in 1,100 patients from 22 countries. Doctors will give the drug, known as LY450139, to patients over 21 months, adjusting the […]